EMEA-002519-PIP03-21
Key facts
| Active substance |
Evenamide
|
| Therapeutic area |
Psychiatry
|
| Decision number |
P/0517/2021
|
| PIP number |
EMEA-002519-PIP03-21
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of schizophrenia
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Newron Pharmaceuticals SpA
E-mail: ravi@anand.ch |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|